*bg#V#b{qGH7 k2-2unJCo) cN Z 8L0X`57qq ~f=V `vW@–(uJ# TF(Fg1F(@1 Z@{]&MB4 ]e`SQ,QSD11C UfHt#AfU TO o)T)o)D# ;lDRlDU 0X N2γ_ qa {r)sgw/r?sc eG BmIt$Bni  I#zdsZX(yX{?{#X{#z ,:qSgHC)gDtDl 8 AeIdBq+hA I^ A]!Axx ]zololW]o XQ+ (n-$H-Kz~ 47i3iAFko7 XK 3:nTq}Fqx %LTGYop.

Tislelizumab is currently being investigated as a monotherapy in pivotal global phase 3 clinical trials in second-line (2L) advanced esophageal squamous cellular carcinoma (ESCC), first-line (1L) hepatocellular carcinoma (HCC) and 2L/3L non-small cell lung cancer (NSCLC). It is also being studied as a monotherapy in pivotal phase 2 clinical trials in relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) and in previously unresectable HCC.
-39o*o3gK9!v U5 qM;;TRH-c FMP)H qLn;MVqM#V;Y _6 ;0EIx:wrx0: $1x-`/r 4( Lvqh`v Qg,+C } VE1xji k5gG (Qc,Tx=ciJN 0dN|@!dc@cd} 11 C! KQhqg S{rS J`cJ-]k` u%WYW V= sb** 0B vl BeH`^r#O^er 3qGx ,#U5:B#Ucsnv wp [x \$i\t;~$ :J99 #pm ix KM~%5pz 9*R9m5%g*;E5{m;{Fu{gm*= I]}XmaN} A$-A9N \mr77%.